The research initiative aims to conduct a comprehensive multi-omics study on the new strain of Vibrio cholerae in Nigeria, starting with sample collection from multiple sites across the country. Following DNA sequencing, the research will transition to an in silico phase, integrating functional genomics of infectious diseases, comparative genomics, variant analysis, and novel peptide therapeutic R&D.

 

By investigating the outbreak dynamics, spread, resistance mechanisms, and genetic variations of the new strain, the research aims to enhance understanding of its pathogenicity and transmission patterns. This will involve whole genome sequencing and the analysis of virulence factors, mobile genetic elements, and antimicrobial resistance genes. Additionally, the study will explore the comparative genomics of different strains, including functional analysis, subsystem categorization, whole genome alignment, pan/core genomics, DNA-DNA hybridization, MLST and ANI and phylogenomic analysis. Through variant analysis, researchers will examine variations in mobile genetic elements, antimicrobial resistance, and virulence factors.

 

The insights gained from these analyses will inform the therapeutic research and development phase, which focuses on identifying and optimizing novel peptide candidates that can effectively target and neutralize the bacteria. This will involve in silico analysis, peptide docking, molecular docking, and preclinical testing to assess the safety and efficacy of the peptides. The ultimate goal is to develop a novel anti-bacterial therapeutic drug based on these peptides, which will be subject to clinical trials before becoming available for widespread use. This research initiative holds the potential to significantly contribute to the control and prevention of cholera outbreaks in Nigeria and beyond.